Safety and efficacy of nilotinib in adult patients with chronic myeloid leukemia: a post-marketing surveillance study in Korea

Ahn, Seo‐Yeon; Kyun Son, Sang; Hyung Lee, Gyu; Kim, Inho; Cheong, June‐Won; Sik Lee, Won; Soo Kim, Byung; Jo, Deog‐Yeon; Won Jung, Chul; Myoung Seong, Chu; Hoon Lee, Jae; Jin Yuh, Young; Kyoung Kim, Min; Ryoo, Hun-Mo; Park, Moo‐Rim; Cho, Su-Hee; Kim, Hoon‐Gu; Young Zang, Dae; Park, Jinny; Kim, Hawk; Lee, Se-Ryeon; Kim, Sung‐Hyun; Hee Chang, Myung; Sup Lee, Ho; Won Choi, Chul; Kwon, Jihyun; Lim, Sung-Nam; Oh, Sukjoong; Joo, Inkyung; Kim, Dong‐Wook

doi:10.5045/br.2022.2021137

Public

Safety and efficacy of nilotinib in adult patients with chronic myeloid leukemia: a post-marketing surveillance study in Korea

Published in Blood Research • Jun 9, 2022

Authors:

Seo‐Yeon Ahn

Sang Kyun Son

Gyu Hyung Lee

Abstract

Background: Nilotinib is a tyrosine kinase inhibitor approved by the Ministry of Food and Drug Safety for frontline and 2nd line treatment of Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). This study aimed to confirm the safety and efficacy of nilotinib in routine clinical prac...

Subject

Nilotinib

Medicine

Adverse effect

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!